Skip to content
Inciteful Med

Understanding Aicardi-Goutières Syndrome (AGS)

Last updated:

Aicardi-Goutières syndrome (AGS) is a rare genetic autoinflammatory disorder, not a contagious viral infection. It causes chronic inflammation in the brain and skin. While there is currently no cure, targeted treatments like JAK inhibitors can help manage symptoms and improve quality of life.

Key Takeaways

  • • AGS is a rare genetic disorder, not a contagious viral infection.
  • • The condition causes chronic immune system overactivity, leading to inflammation primarily in the brain and skin.
  • • AGS is often initially misdiagnosed as a TORCH infection or cerebral palsy due to similar signs on brain scans.
  • • Genetic testing is the most accurate way to confirm an AGS diagnosis and identify the specific mutation involved.
  • • While there is no cure, medications called JAK inhibitors are actively used to help manage systemic inflammation.

Receiving a diagnosis of Aicardi-Goutières syndrome (AGS) can feel overwhelming, especially because it is a rare and complex condition. Understanding the biological “why” behind your child’s symptoms is the first step in moving from the confusion of a “diagnostic odyssey” to a focused plan for care [1][2]. This guide will help you understand the disease, navigate treatments, and build your care team.

Please see the following sections for detailed information:

Three Stabilizing Facts

  1. It is Not an Infection: Although AGS looks like a viral infection on early brain scans, it is a genetic condition [3]. Your child did not “catch” this, and it is not contagious.
  2. The “Storm” Can Stabilize: AGS often begins with a period of intense inflammation (an “encephalopathic phase”). While this period is difficult, the inflammation often eventually plateaus or slows down [4][5].
  3. Targeted Treatments Exist: While there is currently no cure, newer medications called JAK inhibitors are being used to help manage the “interferon storm” and improve systemic symptoms like skin sores [6][7].

What is AGS?

Aicardi-Goutières syndrome (AGS) is a rare genetic autoinflammatory disease that primarily affects the brain and the skin [1][8]. It is classified as a leukodystrophy, a group of disorders that affect the “white matter” (the insulation around nerve fibers) in the brain [9]. In children with AGS, the immune system mistakenly believes there is a constant viral infection, even when no virus is present [3].

The “Type I Interferonopathy”

AGS is the “prototype” of a group of diseases called type I interferonopathies [1].

  • Interferons are proteins the body normally makes to fight off viruses.
  • In AGS, a genetic “glitch” prevents the body from cleaning up its own cellular debris (nucleic acids) [1][10].
  • The immune system sees this debris, mistakes it for a virus, and pumps out a constant stream of Type I Interferon [11]. This leads to chronic inflammation, particularly in the brain, which can cause tissue damage and calcium deposits [12][13].

Why It Is Often Misdiagnosed (Pseudo-TORCH)

Many families experience a “diagnostic odyssey” where doctors first suspect a congenital viral infection (known as a TORCH infection, such as CMV or Rubella) [14][3]. AGS is sometimes called a pseudo-TORCH syndrome because the brain scans look nearly identical to those of an infected newborn [12].

  • Common Overlaps: Both AGS and viral infections can show calcifications (calcium spots) in the brain, a small head size (microcephaly), and liver or spleen enlargement [14][15].
  • The Difference: In AGS, tests for active viruses come back negative, but a specialized blood test may show a high “interferon signature” [16][17].

Incidence and Genetics

AGS is extremely rare, though exact numbers are difficult to track because it is often misdiagnosed as cerebral palsy or a viral infection [18][19]. It is typically caused by mutations in one of at least nine different genes (such as TREX1, RNASEH2B, or IFIH1) [1][20]. However, a small percentage of children may have a clinical diagnosis of AGS without a currently identified genetic mutation [21][22]. Depending on the specific gene, it can be inherited from both parents (autosomal recessive) or can happen as a new, spontaneous mutation in the child (autosomal dominant) [1][23]. Genetic testing is the best way to confirm which type of AGS a child has, which helps doctors predict the disease’s likely course [4].

Frequently Asked Questions

What is Aicardi-Goutières syndrome (AGS)?
AGS is a rare genetic autoinflammatory disease that primarily affects the brain and skin. It causes the immune system to mistakenly attack the body as if it were fighting a constant viral infection, leading to chronic inflammation.
How is AGS different from a viral infection?
While AGS brain scans look similar to those of congenital viral infections like CMV or Rubella, AGS is genetic and not contagious. In AGS, tests for active viruses will be negative, but a specialized blood test may show a high interferon signature.
What are the early warning signs of AGS?
Early signs often include a smaller than normal head size (microcephaly), an enlarged liver or spleen, and periods of severe brain inflammation. Children may also develop skin sores called chilblains on their fingers, toes, or ears, especially in cold weather.
How is Aicardi-Goutières syndrome diagnosed?
Diagnosis typically involves brain imaging (MRI or CT) to look for calcium deposits or white matter changes, along with a blood test to detect a type I interferon signature. Genetic testing is then used to confirm the specific gene mutation causing the syndrome.
Are there any treatments available for AGS?
While there is currently no cure for AGS, targeted medications called JAK inhibitors are used to help manage the severe immune response. These treatments can help reduce systemic inflammation and improve symptoms like skin sores.

Questions for Your Doctor

  • • Which of the known AGS-related genes is affected in our child, or is our child in the small percentage without a currently identified mutation?
  • • Is the 'type I interferon signature' test available at this facility to confirm the diagnosis and monitor treatment?
  • • Has our child's brain imaging (MRI or CT) shown specific markers like basal ganglia calcification or white matter changes?
  • • Should our child be screened immediately for non-neurological symptoms like chilblains, liver issues, or thyroid function?
  • • Are you familiar with the use of JAK inhibitors for managing systemic inflammation in AGS?

Questions for You

  • • When did you first notice changes in your child's development, and were there any 'trigger' events like a fever or infection?
  • • Has your child experienced any unusual skin rashes, particularly on the fingers, toes, or ears, during cold weather?
  • • What are your primary goals for your child's quality of life over the next six months?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Aicardi-Goutières syndrome: A monogenic type I interferonopathy.

    Liu A, Ying S

    Scandinavian journal of immunology 2023; (98(4)):e13314 doi:10.1111/sji.13314.

    PMID: 37515439
  2. 2

    Experiences and Hope in Caregivers of Children With Aicardi Goutières Syndrome.

    Gavazzi F, Martin A, Sevagamoorthy A, et al.

    Journal of child neurology 2025; (40(7)):543-554 doi:10.1177/08830738251341530.

    PMID: 40400365
  3. 3

    Aicardi-Goutières syndrome (AGS): recurrent fetal cardiomyopathy and pseudo-TORCH syndrome.

    Panigrahy N, Bakhru S, Lingappa L, Chirla D

    BMJ case reports 2022; (15(12)) doi:10.1136/bcr-2022-249192.

    PMID: 36581356
  4. 4

    Developmental Outcomes of Aicardi Goutières Syndrome.

    Adang L, Gavazzi F, De Simone M, et al.

    Journal of child neurology 2020; (35(1)):7-16 doi:10.1177/0883073819870944.

    PMID: 31559893
  5. 5

    Late diagnosis and atypical brain imaging of Aicardi-Goutières syndrome: are we failing to diagnose Aicardi-Goutières syndrome-2?

    Svingen L, Goheen M, Godfrey R, et al.

    Developmental medicine and child neurology 2017; (59(12)):1307-1311 doi:10.1111/dmcn.13509.

    PMID: 28762473
  6. 6

    Exploring emerging JAK inhibitors in the treatment of Aicardi-Goutières syndrome.

    Politano D, Tonduti D, Battini R, et al.

    Expert opinion on emerging drugs 2024; 1-19 doi:10.1080/14728214.2024.2445508.

    PMID: 39704072
  7. 7

    JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.

    Frémond ML, Hully M, Fournier B, et al.

    Journal of clinical immunology 2023; (43(6)):1436-1447 doi:10.1007/s10875-023-01500-z.

    PMID: 37171742
  8. 8

    [Aicardi-Goutieres syndrome due to mutation of the IFIH1 gene with pontine involvement. A case report].

    Florido-Rodriguez A, Eiris-Punal J, Barros-Angueira F, et al.

    Revista de neurologia 2016; (63(7)):309-14.

    PMID: 27658362
  9. 9

    Anesthesia for a Patient With Aicardi-Goutières Syndrome: A First Case Report.

    Swenson Schalkwyk AK, Agarwal R

    A&A practice 2021; (15(3)):e01410 doi:10.1213/XAA.0000000000001410.

    PMID: 33684075
  10. 10

    The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis.

    Tever OK, Mentrup T, Chinn IK, et al.

    Cellular and molecular life sciences : CMLS 2025; (82(1)):107 doi:10.1007/s00018-025-05645-5.

    PMID: 40072623
  11. 11

    Generation of three induced pluripotent cell lines (iPSCs) from an Aicardi-Goutières syndrome (AGS) patient harboring a deletion in the genomic locus of the sterile alpha motif and HD domain containing protein 1 (SAMHD1).

    Fuchs NV, Schieck M, Neuenkirch M, et al.

    Stem cell research 2020; (43()):101697 doi:10.1016/j.scr.2019.101697.

    PMID: 32062129
  12. 12

    [Aicardi-Goutieres syndrome: a Mendelian mimic of congenital infection].

    Lebon P

    Virologie (Montrouge, France) 2009; (13(6)):297-304 doi:10.1684/13-6.2011.297-304-article-1.

    PMID: 36151662
  13. 13

    Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome.

    Jafarpour S, Suddock J, Hawes D, Santoro JD

    Journal of clinical immunology 2024; (44(3)):68 doi:10.1007/s10875-024-01672-2.

    PMID: 38381212
  14. 14

    Clinical and neuroradiologic variability of Aicardi-Goutiéres syndrome: Two siblings with RNASEH2C mutation and a boy with TREX1 mutation.

    Uyur Yalçın E, Maraş Genç H, Kara B

    The Turkish journal of pediatrics 2015; (57(5)):504-8.

    PMID: 27411419
  15. 15

    SAMHD1 compound heterozygous rare variants associated with moyamoya and mitral valve disease in the absence of other features of Aicardi-Goutières syndrome.

    Karla AR, Pinard A, Boerio ML, et al.

    American journal of medical genetics. Part A 2024; (194(4)):e63486 doi:10.1002/ajmg.a.63486.

    PMID: 38041217
  16. 16

    PNPT1 mutations may cause Aicardi-Goutières-Syndrome.

    Bamborschke D, Kreutzer M, Koy A, et al.

    Brain & development 2021; (43(2)):320-324 doi:10.1016/j.braindev.2020.10.005.

    PMID: 33158637
  17. 17

    Aicardi-Goutières Syndrome: Brief Case Report.

    Moscote-Salazar LR, Calderon-Miranda WG, Deluquez Baute RV, et al.

    Journal of pediatric neurosciences 2018; (13(1)):88-90 doi:10.4103/JPN.JPN_67_17.

    PMID: 29899779
  18. 18

    Analysis of clinical characteristics of children with Aicardi-Goutieres syndrome in China.

    Wang W, Wang W, He TY, et al.

    World journal of pediatrics : WJP 2022; (18(7)):490-497 doi:10.1007/s12519-022-00545-1.

    PMID: 35551623
  19. 19

    Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.

    Videira G, Malaquias MJ, Laranjinha I, et al.

    Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.

    PMID: 32258229
  20. 20

    The c.529G>A (p.Ala177Thr) RNASEH2B Gene Pathogenic Variant as a First-Line Genetic Test for Aicardi-Goutières Syndrome: A Case Series of Four Moroccan Families.

    Ouhenach M, Nada A, Lyahyai J, Sefiani A

    American journal of medical genetics. Part A 2025; (197(6)):e63997 doi:10.1002/ajmg.a.63997.

    PMID: 39890436
  21. 21

    Phenotypic and Molecular Spectrum of Aicardi-Goutières Syndrome: A Study of 24 Patients.

    Al Mutairi F, Alfadhel M, Nashabat M, et al.

    Pediatric neurology 2018; (78()):35-40 doi:10.1016/j.pediatrneurol.2017.09.002.

    PMID: 29239743
  22. 22

    Nucleotide metabolism, leukodystrophies, and CNS pathology.

    Gavazzi F, Gonzalez CD, Arnold K, et al.

    Journal of inherited metabolic disease 2024; (47(5)):860-875 doi:10.1002/jimd.12721.

    PMID: 38421058
  23. 23

    An overview of genetic mutations in Aicardi-Goutières syndrome in Iranian population.

    Khalilian S, Fathi M, Miryounesi M, Ghafouri-Fard S

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(2)):999-1007 doi:10.1007/s10072-024-07824-x.

    PMID: 39470906

This guide to Aicardi-Goutières syndrome is for informational purposes only. Always consult your child's neurologist or geneticist for specific medical advice, testing, and treatment planning.

Stay up to date

Get notified when new research about Aicardi-Goutières syndrome is published.

No spam. Unsubscribe anytime.